Genetic Technologies Reported Monday, geneType Identifies 79.5% Of People Tested In U.S., Australia Are At Risk Of Serious Disease
Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to share the power of the geneType test in identifying risk and improving the health of populations worldwide. Since the geneType Risk Assessment Tests became available, GTG has tested a statistically significant number of people in Australia and the US. These results have revealed a compelling statistic: 79.5% of individuals tested*0F1 showed an elevated risk for at least one disease. GTG believes this is a significant finding driving increased surveillance and screening which will ultimately lead to early detection, early intervention and, ultimately, save lives.